Can we really distinguish 'responders' from 'non‐responders' to myopia control interventions?
Saved in:
| Title: | Can we really distinguish 'responders' from 'non‐responders' to myopia control interventions? |
|---|---|
| Authors: | Brennan, Noel A. (AUTHOR), Nixon, Alex D. (AUTHOR), Cheng, Xu (AUTHOR), Bullimore, Mark A. (AUTHOR) |
| Source: | Ophthalmic & Physiological Optics. Nov2024, Vol. 44 Issue 7, p1363-1367. 5p. |
| Subjects: | Myopia, Atropine, Age groups, Sample size (Statistics), Lamps |
| Abstract: | Purpose: It is common to hear talk of 'responders' and 'non‐responders' with respect to myopia control interventions. We consider the reality of distinguishing these sub‐groups using data from the first year of the Low‐concentration Atropine for Myopia Progression (LAMP) study. Methods: The first year of the LAMP study was a robustly designed, placebo‐controlled trial of three different low concentrations of atropine using a large sample size (N > 100 randomised to each group). The authors subsequently published mean axial elongation and myopia progression rates by age group. We used these data to calculate efficacy in terms of both absolute reduction in myopic progression and absolute reduction in axial elongation for each of the different atropine concentrations at each age group. We then compared these efficacy data to the overall progression for each of the two progression metrics. Results: Plotting efficacy as a function of overall myopia progression and axial elongation for each of the different atropine concentrations demonstrates the invariant nature of efficacy, in terms of clinically meaningful reduction in progression, despite a substantial range of underlying overall progression. That is, faster progressors—the so‐called non‐responders—achieved similar reduction in axial elongation and myopia progression as the slower progressors—the so‐called responders—within the various atropine treatment groups. Conclusion: The use of the terms, responders and non‐responders, during myopia progression interventions is not supported by evidence. Those designated as such may simply be slower or faster progressors, who, on average achieve the same benefit from treatment. [ABSTRACT FROM AUTHOR] |
| Copyright of Ophthalmic & Physiological Optics is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Purpose: It is common to hear talk of 'responders' and 'non‐responders' with respect to myopia control interventions. We consider the reality of distinguishing these sub‐groups using data from the first year of the Low‐concentration Atropine for Myopia Progression (LAMP) study. Methods: The first year of the LAMP study was a robustly designed, placebo‐controlled trial of three different low concentrations of atropine using a large sample size (N > 100 randomised to each group). The authors subsequently published mean axial elongation and myopia progression rates by age group. We used these data to calculate efficacy in terms of both absolute reduction in myopic progression and absolute reduction in axial elongation for each of the different atropine concentrations at each age group. We then compared these efficacy data to the overall progression for each of the two progression metrics. Results: Plotting efficacy as a function of overall myopia progression and axial elongation for each of the different atropine concentrations demonstrates the invariant nature of efficacy, in terms of clinically meaningful reduction in progression, despite a substantial range of underlying overall progression. That is, faster progressors—the so‐called non‐responders—achieved similar reduction in axial elongation and myopia progression as the slower progressors—the so‐called responders—within the various atropine treatment groups. Conclusion: The use of the terms, responders and non‐responders, during myopia progression interventions is not supported by evidence. Those designated as such may simply be slower or faster progressors, who, on average achieve the same benefit from treatment. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 02755408 |
| DOI: | 10.1111/opo.13379 |
